Brilinta

Product manufactured by Cardinal Health

Application Nr Approved Date Route Status External Links
NDA022433 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Brilinta Is Indicated To Reduce The Rate Of Cardiovascular Death, Myocardial Infarction, And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Myocardial Infarction (Mi). For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Brilinta Also Reduces The Rate Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs [ See Clinical Studies (14.1) ] . Brilinta Is A P2y 12 Platelet Inhibitor Indicated To Reduce The Rate Of Cardiovascular Death, Myocardial Infarction, And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Myocardial Infarction (Mi). For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Brilinta Also Reduces The Rate Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ticagrelor TICAGRELOR ZINC28957444

Comments